Effect Of Atorvastatin On Vascular Endothelial Function In Essential Hypertensive Patients With Impaired Glucose Tolerance

Objective: To investigate the effects of atorvastatin on vascular endothelialfunction in essential hypertensive patients with impaired glucose tolerance(IGT).Methods: The research enrolled the essential hypertensive patients with impairedglucose tolerance. A case-controlled study was conducted in96patients which weredivided randomly into conventional therapeutic group and atorvastatin treated group.46patients in atorvastatin treated group and50control subjects in conventional therapeuticgroup. Flow-mediated dilation(FMD)and endothelium-independent dilatation(EID)weremeasured with high-resolution ultrosonography before and after8weeks treatment.Plasmalevels of CD31+/Annexin V+EMPs were measured before and8week’s treatment by flowcytometric analysis.Results: In atorvastatin group and control group，Flow-mediated dilation (FMD)were improved after8weeks treatment.(atorvastatin group：5.33%±0.39%vs10.16%±0.46%，P <0.01；control group：5.27%±0.47%vs7.92%±0.56%，P <0.01)， whileno changes in endothelium-independent dilatation(EID) were found. FMD was improvedmore greatly in atorvastatin group than control group(P <0.01)Plasma EMPs levels had no significant difference between atorvastatin treated groupand control group before treatment. After therapy for8weeks the levels of plasma EMPsin atorvastatin treatment group [(2342.5±856.2)/ml vs (1806.7±761.7)/ml，P<0.01]wassignificantly decreased. However the levels of plasma EMPs was no significant differencein control group[(2251.8±832.5)/ml vs (2152.5±815.1)/ml，P<0.05]. Conclusions: Atorvastatin improves the vascular endothelial function in essentialhypertensive patients with impaired glucose tolerance.